Introduction
In the past 15 y, erectile dysfunction (ED) has witnessed an enormous growth in basic scientific interest, which has been translated impressively to the development of several treatment options. Despite the established efficacy and safety of intracavernosal pharmacotherapy, the demands for a drug with the following characteristics remained high: oral administration before sexual activity, rapid therapeutic effect, natural or 'physiologic' erections, reproducible and reliable predictive result, minor adverse events, pharmacologic effects limited to the brief period of sexual encounter, and limited interactions with other drugs. The availability of sildenafil, a specific phosphodiesterase 5 inhibitor, in the market as the first efficacious and safe oral treatment for ED, in conjunction with the high prevalence of ED and the extensive media coverage of the new drug, led to sildenafil being the most recognized pharmaceutical product in the world. From a marketing perspective, the product also became the focus of media attention and publicity for the manufacturer.
This article reviews all the available data from published clinical trials and independent studies. In addition, special reference is also made to the dramatic changes in everyday clinical practice witnessed in the field during the last 3 y due to the availability of sildenafil.
Efficacy in clinical trials
Clinical trials establishing the efficacy and safety of sildenafil as a treatment for ED have been conducted worldwide (data on file; Pfizer, Inc, New York, NY, USA). 1 -10 All of these studies were double-blind, placebo-controlled trials with treatment periods of 8 -12 weeks that evaluated flexible doses of sildenafil (25, 50 or 100 mg) in men with ED of broadspectrum origins. A significant treatment effect was observed in all of these trials for sildenafil compared with placebo, and treatment response rates were similar across all trials (Figures 1 and 2) . A review of the use of sildenafil in diverse subgroup populations follows. neuropathy and peripheral vascular disease. In two trials conducted in the USA involving men with ED and type 1 or type 2 diabetes, 51 -56% of the sildenafil-treated patients reported improved erections compared with 10 -12% of those randomized to placebo. 11, 12 One of these two trials also assessed the effect of number of diabetic complications (retinopathy, nephropathy, cardiovascular complications and neuropathy) and severity of diabetes (as judged by glycosylated hemoglobin levels) on the response rate to treatment. 11 The most recently reported study involving patients with type 2 diabetes reports a 64.6% response rate to sildenafil compared with a 10.5% response rate in diabetic patients receiving placebo. 13 Sildenafil was effective in improving ED in these studies, even in cases of poor glycemic control; the response rate, however, for patients with multiple chronic complications was lower, reflecting the severity of the disease. A retrospective analysis of combined data from 11 double-blind, placebo-controlled trials of sildenafil (which included 152 and 822 patients with type 1 and 2 diabetes, respectively, and 1693 patients without diabetes) confirmed that although treatment response was lower for patients with diabetes compared with those without diabetes, the efficacy of sildenafil was similar for men with type 1 and type 2 diabetes, with more than three times as many men receiving sildenafil reporting significant improvement in erectile function compared with those receiving placebo. 14 
Patients with depression
ED and depression are both highly prevalent conditions that frequently coexist. Although serotonin reuptake inhibitors (SRIs) are highly effective in treating patients with depression, sexual dysfunction (SD) is commonly associated with use of SRIs and can compromise treatment compliance. A retrospective analysis of 10 randomized trials evaluated whether sildenafil (5 -200 mg) could alleviate the symptoms of SD in men with ED taking concomitant SRIs. In a subgroup of 92 men with ED, sildenafil (n ¼ 62) significantly improved the frequency of both ejaculations and orgasm compared with placebo (n ¼ 30). 15 Significant improvement in sexual function was also demonstrated with sildenafil in a prospective, 6-week, double-blind, placebo-controlled trial in 90 men with clinically controlled major depression and SRI-associated SD. 16 Sildenafil effectively reversed SRI-associated SD, allowing patients to continue the antidepressant at the dose that effectively treated their depression.
Spinal cord injury patients
In the USA alone, 60% of traumatic spinal cord injuries (SCIs) occur in people aged 16 -30 y, of whom approximately 80% are men and approximately half will experience ED. 17 Two double-blind, placebo-controlled trials have evaluated sildenafil as therapy for ED in men with SCIs. The initial trial evaluated the efficacy and safety of sildenafil, 50 mg, in men with SCIs with at least a partial response to penile vibratory stimulation. Of the 26 men evaluated, 65 and 75% had satisfactory erections after treatment with sildenafil compared with 7 and 8% following treatment with placebo in a clinical and home setting, respectively. 18, 19 These results were confirmed in another double-blind, placebo-controlled, flexible-dose (25, 50 and 100 mg) trial in 178 patients, where 76% of men with SCIs reported improved erections with sildenafil compared with 4% of patients receiving placebo. 20 Such data clearly show the high efficacy of sildenafil in SCI patients with preserved reflexogenic erections.
Patients with multiple sclerosis
ED is a common complication in men with multiple sclerosis, a disease that occurs in relatively young patients, and contributes significantly to the reduced quality of life associated with multiple sclerosis. The effect of sildenafil (25 -100 mg) on erectile function and patient quality of life was assessed in a double-blind, placebo-controlled trial in 217 men with multiple sclerosis and ED. After 12 weeks of treatment, 89% of patients receiving sildenafil compared with 24% of patients receiving placebo reported improved erections and significant improvements in five general quality-of-life areas. 21, 22 Renal failure and dialysis patients SD, including ED and loss of libido, is a common finding in men with chronic renal failure. Several studies have concluded that sildenafil is effective and well tolerated in patients undergoing long-term maintenance dialysis. One study reported that sildenafil (50 mg) produced a 60% increase in sexual satisfaction and performance in nine men with ED undergoing maintenance hemodialysis. 23 Significant improvements in frequency of penetration and maintenance of erections were also reported in 14 male patients undergoing dialysis who received at least 4 weeks of treatment with sildenafil. 24 Similar findings were reported in 35 men undergoing long-term dialysis who were treated with sildenafil (25 -100 mg) for at least 6 months. An increase in total International Index of Erectile Function score of more than 10 points was reported in 80% of these patients with sildenafil therapy. Overall, 77% of patients were satisfied with treatment. 25 
Patients with cardiovascular disease
Men with cardiovascular disease are more likely to have ED than the general male population because both conditions share a number of risk factors. The efficacy and safety of sildenafil for the treatment of ED in 224 men with stable cardiovascular disease who were not receiving concomitant nitrate therapy were evaluated in a 12-week, double-blind, placebocontrolled, flexible-dose (25 -100 mg) study conducted in Sweden. Treatment with sildenafil was associated with significant increases in the ability to achieve and maintain erections compared with placebo. 26 
Previous users of intracavernosal injection therapy
Two recent studies have reported treatment outcomes for patients with ED who were successfully managed with intracavernosal injection therapy with prostaglandin E 1 alone or in combination with papaverine and phentolamine who switched to oral therapy with sildenafil. In the first study, more than two thirds of the 176 patients who received sildenafil for 12 weeks reported that treatment satisfaction was maintained or increased with a change to sildenafil. 27 In the second study, 75% of patients responded to sildenafil; 64% of these responders elected to continue taking sildenafil after a 3-month trial period. Although the efficacy rates were similar, the study indicated that patients used the oral therapy more often, and most patients elected to continue to use sildenafil therapy after the end of the study. 28 These results demonstrate that, even in patients who were highly successful users of intracavernosal therapy, satisfaction improved with sildenafil.
Patients undergoing radical prostatectomy
Of the more than 200 000 men diagnosed as having prostate cancer annually in the USA, approximately 50 000 will undergo radical retropubic prostatectomy. 29 ED occurs frequently following radical retropubic prostatectomy, affecting nearly 100% of patients if the neurovascular bundles are not spared and approximately 40 -70% of patients if nervesparing techniques are used. A number of studies have evaluated the use of sildenafil in men with ED following radical retropubic prostatectomy. Response rates with sildenafil in this patient group depend on whether nerve-sparing techniques are used, with the highest response rate in bilateral nerve-sparing procedures (80%), followed by 50% in unilateral nerve-sparing surgery, and only 15% in the absence of nerve-sparing techniques. 30 -32 In a recent study, Zagaja et al 32 showed that younger patients and those treated with bilateral nervesparing technique are more likely to be potent postoperatively. On the other hand, early nonresponse to sildenafil in patients who have undergone radical prostatectomy should not be considered as a failure, since the likelihood of response increases over time. A study reported by Hong and colleagues 33 indicated that the response to sildenafil depends on the interval between radical prostatectomy and starting treatment with sildenafil. Up to 6 months after surgery the response rate was 26%, but this improved with time and the treatment satisfaction rate peaked at 60% between 18 months and 2 y after surgery.
Patients with Parkinson's disease
Men with Parkinson's disease often report ED, diminished sexual activity and sexual dissatisfaction. In an open-label pilot study, sildenafil significantly improved sexual function and significantly increased overall sexual satisfaction in 10 men with ED and Parkinson's disease. 34 In a related study, sildenafil was associated with substantial improvements in erectile function and reduction in patient-assessed severity of their erection problem compared with placebo in men with ED and Parkinson's disease (n ¼ 10) or multiple system atrophy, an uncommon cause of Parkinsonism often associated with autonomic failure (n ¼ 6). 35 However, in three men with postural hypotension secondary to autonomic failure in multiple system atrophy, a significant decrease in mean blood pressure was noted with sildenafil, suggesting that caution should be exercised when considering sildenafil for patients with this relatively rare neurologic condition.
Spina bifida patients
Advances in medical and surgical treatment have greatly increased the life expectancy of individuals with neural tube closure defects such as spina bifida. With affected patients living well into the adult years, it is now recognized that ED may be an associated disorder for many of these patients. Assessment of the effectiveness of sildenafil in men with ED and spina bifida demonstrated that treatment with sildenafil resulted in improved erectile function in 80% of men (12 of 15) with spina bifida given 25 or 50 mg of sildenafil. A significant increase in sexual confidence was also noted. 36 
Transplant recipients
There is a high incidence of ED in heart, kidney and multiorgan transplant recipients. Accounts of sildenafil use in this population have reported that approximately 60% of transplant recipients responded to treatment with sildenafil. Additional concerns that sildenafil might alter cyclosporine concentrations or decrease perfusion to grafted kidneys appear to be unfounded. Although cyclosporine and sildenafil are both metabolized via the hepatic microsomal cytochrome P450 isozyme 3A4 (CYP3A4) enzymatic pathway, neither an alteration in cyclosporine levels nor a change in cyclosporine dosage was required when sildenafil was administered. 37 -39 Patient and partner treatment satisfaction and effects on quality of life
In various clinical trials, 28,40 treatment satisfaction with sildenafil was assessed in patients and found to be favorable, with 65% of patients stating that they were satisfied with sildenafil 40 and 77 -85% of patients electing to continue treatment with sildenafil. Interestingly, although treatment satisfaction was shown to correlate with ED severity (severe ED, 41%; moderate ED, 78%; mild ED, 100%) and cause (neurologic cause, 56%; diabetes, 58%; radical prostatectomy, 35%; psychogenic cause, 89%; vasculogenic cause, 86%), no particular characteristic predicted absolute failure with sildenafil. 41 Similar findings were shown in an independent study in 1996, 42 which also assessed previously used treatments and found generally low rates of satisfaction with oral treatments, hormonal treatments, intraurethral suppository treatment, intracavernosal injection therapy and vacuum constriction devices. Although all these options have been shown to be effective in treating ED, a clear preference for the least invasive forms of therapy has been demonstrated.
When partner assessments of patient ability to achieve and maintain an erection and their own level of satisfaction with intercourse were obtained in various trials, they usually corroborated patient assessments of significant treatment effects with sildenafil. For example, this was seen in men with concomitant ED and diabetes 43 and renal failure. 44 Quality of life plays an increasingly more important role in assessing treatment success. Two trials in patients with SCI 20 and multiple sclerosis 22 reported improved condition-specific and general quality-of-life parameters in sildenafil-treated men compared with those receiving placebo.
In contrast to the double-blind, placebo-controlled trials in which selection of study participants was restricted by specific inclusion and exclusion criteria, recent accounts of sildenafil use in a clinical practice setting provide information on the effectiveness, tolerability, and safety of sildenafil in the general population of men seeking treatment for ED. The effectiveness of sildenafil in these unselected populations of men with ED has been similar to that reported in double-blind trials, with improvement in ability to achieve erections reported by 68% and 71% of patients in two studies. One of the largest independent studies evaluated 267 patients treated with sildenafil during the initial months after approval in the USA. 41 Of this large series of patients, 85% wished to continue treatment, 65% were moderately or very satisfied, and 35% reported at least one adverse event, but no patients discontinued treatment because of adverse events or reported a serious adverse event.
Overall safety
The most commonly reported adverse events with sildenafil were usually transient, mild to moderate in nature, and infrequently a cause for discontinuation of treatment. The frequency of reported adverse events was comparable in clinical trials and in clinical practice and included headache (16% vs 7 -25%), facial flushing (10% vs 7 -34%), nasal congestion (4% vs 4 -19%), dyspepsia (7% vs 1 -11%), and abnormal vision (predominantly a faint blue tinge to vision; 3% vs 1 -6%), respectively. 45, 46 The rate of discontinuation because of adverse events in sildenafil-treated patients was 2.5% in controlled trials compared with 2.3% for placebo. In the clinical practice setting, this has been recorded as ranging from 0 -9%.
A more recent study of 256 patients with ED reported that 32% of patients experienced adverse events; however, the authors concluded that the adverse-event profile was dose related, transient, and mild in nature and that sildenafil remained a well-tolerated treatment for ED. 47 
Cardiovascular safety
New studies show that sildenafil does not increase the workload of the heart in humans with severe coronary artery disease. 48 In addition, sildenafil was Sildenafil citrate: lessons learned DG Hatzichristou not associated with adverse hemodynamic effects in patients with ischemic heart disease and chronic heart failure 47 and was equally effective and well tolerated in patients taking antihypertensive agents as in those patients not taking blood pressure medication. 49, 50 Aside from the known contraindication of sildenafil in nitrate users, caution should also be exercised when patients with cardiovascular disease resume sexual activity as a result of receiving any treatment for ED. To that effect, a consensus panel of experts recently issued recommendations for the management of ED in patients with cardiovascular disease. 51 Within their stratification of cardiac risk, most patients with ED would fall into the lowcardiac-risk category (Table 1) . Thus, these patients could safely resume sexual activity, whereas those in higher-risk categories would be encouraged to undergo further cardiovascular evaluation and treatment by experts.
Are ED patients treated properly?
Because many more men are seeking help for the condition, primary care physicians are increasingly involved in making decisions about the evaluation and treatment of these men. Today most ED patients are initially treated by general practitioners, and many specialists other than urologists, such as diabetologists, have also become involved in ED management.
Feedback has indicated, however, that when sildenafil is prescribed by nonspecialists, the response rates appear to be lower than those achieved by urologists or other ED specialists. There may be several reasons for this. The most likely reason is that nonspecialists may have insufficient background knowledge to be able to evaluate, educate, and treat ED patients. Most physicians have never been educated on sexual function and dysfunction or on taking and interpreting a sexual history. Moreover, they are not convinced about the medical relevance of treating ED. In addition, primary care physicians are typically extremely busy. Often, lack of time does not allow them to perform a detailed sexual history and provide appropriate physicianpatient dialogue.
Despite the fact that many disorders are associated with ED, including hypertension, diabetes mellitus, hypercholesterolemia, and renal insufficiency, physicians are not proactive in asking about erectile function; 52 ED is only diagnosed 1% of the time with other medical conditions, such as diabetes mellitus (0.4%) or hypertension (0.2%) (Scott-Levin survey, March 2000). Studies have shown that more than half of the general practitioners do not feel comfortable using ED treatments, and most of them do not propose second-or third-line therapies to their patients who do not respond to sildenafil. 53 In fact, most ED patients do not have a follow-up visit, which is crucial to solve treatment problems, such as administration, efficacy, adverse effects, partner's acceptance, new medical conditions, and changes in potency status. 54 As a consequence, patients may not receive adequate instructions with their sildenafil prescriptions. In a study conducted recently in our unit, 56% of the patients who visited our outpatient clinic as 'sildenafil failures' had used the drug incorrectly. Of these patients, 55% responded to sildenafil after receiving appropriate dose titration and instructions on administration. 55 
Why do patients not seek treatment for ED?
The high prevalence of ED in conjunction with the extensive media coverage of the new drug led to the projection for explosive sales of the ED market. It is true that the number of patients seeking treatment for ED has increased dramatically in the last 3 y; marketing data show that more than 500 000 physicians have prescribed more than 45 million prescriptions for more than 15 million men worldwide ( > 400 million tablets dispensed, accounting for six tablets dispensed every second). In the USA, more than 10 million men have been treated, representing almost 1 in 5 men older than 40 y. Sixty percent of these men are between the ages of 50 and 69 y, and the average use is once every 8 to 11 days. Actually, sildenafil covers 90% of the drug prescriptions for ED (Pfizer Inc data on file and IMS Health). However, only 17% of men 40 -70 y of age admit that they have experienced ED (Yankelovich Partners National Survey, August 1999), despite the fact that the prevalence of ED in this age group is 52%.
Why do ED patients not seek treatment? There are three possible reasons. First, patients are reluctant to discuss sexual issues, whereas physicians do not feel comfortable opening the discussion; data show that 71% of the patients believe ED would not be recognized as a medical problem, whereas 68% fear that discussing sexuality may embarrass their physicians. 56 Second, elderly men lose interest in sex, and with advancing age, normal erections are not an absolute prerequisite for a sexually active life. 57 Third, coverage of sildenafil by health insurance plans is limited. 58 Although effective therapies exist for health conditions that diminish quality of life, there remain hurdles in health care delivery that may limit access to such therapies. The practical inability within the health care community to compare health care interventions, such as treatments for ED with those for asthma, hypertension, or other conditions, prevents the optimal allocation of health care services, despite the fact that the cost-effectiveness of sildenafil treatment compared favorably with that of accepted therapies for other medical conditions. 58, 59 Suggestions for optimizing treatment with sildenafil A significant issue in treating ED patients is to acknowledge the importance of the psychogenic component of ED and the specific relationship and cultural aspects of the condition. 60 A partner's reluctance to provide support or unrealistic expectations may negatively influence the response to treatment. Treatment with sildenafil is associated with a certain level of expectation of success; it is, therefore, essential to educate both patient and partner on how to optimize treatment success with sildenafil before seeking alternate treatment options.
Regardless of the treatment option chosen, follow-up is essential to ensure the best treatment outcome. Monitoring of adverse events, assessing success or lack of success with the chosen treatment, determining if the female partner may have SD (such as vaginal dryness) that requires intervention and prevents the successful treatment of the ED, and considering whether an alteration in dose or treatment would be helpful should all be included in the follow-up visit. Referral for specialist care with a urologist, endocrinologist, sex therapist, relationship counselor, or other appropriate specialist remains an important consideration in managing the patient with ED. For example, some patients with ED are difficult to treat because of an underlying pathologic condition, for example, radical prostatectomy.
In patients who do not respond to sildenafil, second-line (intracavernosal injection) and thirdline (penile prosthesis) treatment options should be offered, since these forms of treatment have shown reasonable response and satisfaction rates in such patients.
Diagnosis and treatment of ED should not be delayed and should be efficient and clinically thorough in approach, but the treatment prescribed should produce a reliable effect within an acceptably short period before the desired sexual activity. Because sildenafil is the most commonly used treatment of ED, the following FAST acronym is a useful reminder of the essential aspects in managing ED patients (Table 2 ).
Follow-up of patients. ED should be treated in the same way as other chronic conditions such as hypertension and diabetes. Follow-up visits are Adjustment of dosing. Careful attention to prescribing instructions is necessary. Also, in patients possibly slower to respond, such as those who are re-establishing sexual intimacy after a period of abstinence, trying at least six times at the maximum tolerated dose may be necessary.
Sexual stimulation. Sildenafil enhances the physiologic response; therefore, sexual stimulation is essential and needs be given at the appropriate time after dosing; sexual activity should start any time from half an hour after dosing in the fasted state to 60 min or longer if sildenafil is taken after a meal. It may be also necessary to consider educating the patient and partner on suitable methods of stimulation that are appropriate to the age of the couple.
Titrating to the maximum tolerated dose. Titrating to the maximum tolerated dose (usually 100 mg) is essential and may maximize response rates to sildenafil. Most patients tend to end up using the 100-mg dose. This simple rule is surprisingly often forgotten or is not possible because the clinician fails to establish the response to the initial 50-mg doses of sildenafil.
Conclusion
After more than 11 000 patient-years of observation in clinical trials, the efficacy and safety profile of sildenafil has changed little in the 3 y since the drug became available for the treatment of ED. Sildenafil is effective and well tolerated in patients with ED of broad-spectrum origins and a wide range of comorbidities. In addition, patients previously treated with other ED therapies have successfully switched to treatment with sildenafil.
New studies confirm the modest vasodilatory properties and lack of deleterious effects in the vast majority of patients with cardiovascular disease. Concomitant administration of nitrates or nitric oxide donor drugs within 24 h remains an important contraindication to the use of sildenafil. However, the cardiac risk associated with sexual activity should be an important consideration before advising patients with cardiovascular disease to resume having sex or initiating any therapy for ED.
Public awareness of the common occurrence of ED and its potentially favorable response to treatment increased dramatically with the introduction of sildenafil. Consequently, the number of patients seeking treatment for ED, often by consulting their primary care physician, has also increased. Primary care physicians should be able to diagnose ED and be aware of the common risk factors associated with ED. Asking about sexual function at regular followup visits might enable earlier diagnosis and treatment of ED in patients with these associated risk factors. Likewise, patients seeking treatment for ED who have no history of medical conditions commonly associated with ED should be screened for them.
Several educational and awareness activities have taken place during the last 2 -3 y, and guidelines for the evaluation and treatment of ED have been published by several scientific societies and consensus panels, but there is no doubt that the level of sexual education of physicians remains poor. 
